Insider Buy ·Filed Aug 10, 2026

PRTA

PROTHENA CORP PUBLIC LTD CO
BULLISH
Impact 5/10
Horizonweeks Processed1mo ago SEC0001045463-26-000010
Insider cluster: 1 insiders, $323K total
Actionable Insight ▲ Bullish

The 10% owner's open-market purchase is a modest bullish signal, but the small size relative to market cap limits its impact. Monitor for any subsequent filings (e.g., 8-K, press release) that might explain the insider's conviction, and watch for any additional insider buying or selling in the coming weeks to confirm the signal.

DirectionBullish
Confidencemedium
Horizonweeks
Latest settled — T+20d ⚠ clustered
PRTA ▲ +4.61% at T+20d
LONG call ✓ call won +4.61% · α vs SPY +5.52% · entry $9.12 → $9.54
Next anchor: T+60d in 5w
Latest observation: T+37 +11.43% FF3 residual α
Entry anchored
Aug 10, 2026
via day open
T+1d
+1.10%
call +1.10% · α +1.42%
$9.22
settled 7w ago
T+5d
-2.63%
call -2.63% · α -2.58%
$8.88
settled 7w ago
T+20d
+4.61%
call +4.61% · α +5.52%
$9.54
settled 24d ago
T+60d
—
call — · α —
—
in 5w

Price Chart

Loading chart...

Executive Summary

William P. Scully, a 10% owner of Prothena, made a single-day open-market purchase of 37,500 shares for $323K on August 7, 2026, at $8.62 per share. This is a conviction buy from a major insider, representing 0.07% of the company's $459M market cap, which is a modest but notable signal given the insider's status and the lack of any recent insider selling at this level.

Key Financial Metrics

Direction
buying
Total Value
$323.2K
Insiders
1

Key Facts

  • 10% owner William P. Scully purchased 37,500 shares for $323,220 on August 7, 2026.
  • The purchase was made at $8.62 per share, an open-market transaction.
  • Total purchase value represents 0.07% of Prothena's $459M market cap.
  • This is a single-insider conviction buy, not a cluster, but from a significant insider (10% owner).

Financial Impact

$323K insider purchase by 10% owner, representing 0.07% of market cap.

insider ownership

Risk Factors

  • The purchase is small relative to market cap (0.07%), limiting its signaling power.
  • Historical performance on PRTA shows a 44% win rate at T+20, suggesting past insider signals have been unreliable.
  • The stock has a 67% bullish analyst consensus, which may already be priced in.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
67% bullish (12 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
INSIDER-BUY Data (Synthetic)0001045463-26-000010
10 reports for PRTA
Performance horizon
50% Hit rate 2 of 4 directional calls best @ T+60▲ +14.11%Jun 12, 2026
Filters
Rows
Reports for PRTA — sortable, filterable
TypeNow
Sep 3, 2026
28d ago
Insider Buy
NEUTRAL ★ 3/10
$9.82 $8.86▼ −9.78%▼ −8.57%$8.44 (−14.05%)
Aug 21, 2026
6w ago
Insider Buy
BULLISH ★ 4/10
$9.45 $9.33▼ −1.27%▼ −1.74%$8.44 (−10.69%)
Aug 10, 2026
7w ago
Insider Buy
BULLISH ★ 5/10
$9.12 $8.88▼ −2.63%▼ −2.58%$8.44 (−7.46%)
Jul 31, 2026
9w ago
Insider Cluster
NEUTRAL ★ 2/10
$8.12 $8.76▲ +7.88%▲ +4.37%$8.44 (+3.94%)
Jun 18, 2026
15w ago
Insider Buy
BULLISH ★ 5/10
$8.93 $9.27▲ +3.81%▲ +5.47%$8.44 (−5.49%)
Jun 12, 2026
15w ago
Insider Buy
BULLISH ★ 5/10
$8.15 $9.15▲ +12.27%▲ +13.65%$8.44 (+3.56%)
May 14, 2026
20w ago
3
NEUTRAL ★ 2/10
$9.76 $9.83▲ +0.72%▼ −0.25%$8.44 (−13.52%)
May 7, 2026
21w ago
8-K
BULLISH ★ 8/10
$10.73 $9.86▼ −8.11%▼ −9.57%$8.44 (−21.34%)
Mar 27, 2026
26w ago
DEFA14A
NEUTRAL ★ 3/10
$9.25 $10.36▲ +12.00%▲ +7.70%$8.44 (−8.76%)
Mar 3, 2026
30w ago
EFFECT
NEUTRAL ★ 3/10
$9.36 $9.77▲ +4.38%▲ +4.86%$8.44 (−9.83%)
Showing 10 of 10

US Market Status

Market Open — Closes in 51m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access